Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
49 hedge funds and large institutions have $21.9M invested in Sierra Oncology, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 13 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
17% less funds holding
Funds holding: 59 → 49 (-10)
73% less capital invested
Capital invested by funds: $81.2M → $21.9M (-$59.4M)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$860K |
| 2 |
TI
Telemetry Investments
New York
|
+$771K |
| 3 |
Renaissance Technologies
New York
|
+$505K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$500K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$376K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$8.26M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.92M |
| 3 |
AC
Armistice Capital
New York
|
-$2.67M |
| 4 |
A
Abingworth
London,
United Kingdom
|
-$1.39M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.23M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
51
Candriam SCA
Strassen, Luxembourg,
Luxembourg
| – | -$1.23M | -18,000 | Closed |
|
|
O
52
OrbiMed
New York
| – | -$542K | -7,928 | Closed |
|
|
FAM
53
Fred Alger Management
New York
| – | -$127K | -1,850 | Closed |
|
54
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$70K | -1,026 | Closed |
|
55
Millennium Management
New York
| – | -$67K | -977 | Closed |
|
56
Russell Investments Group
London,
United Kingdom
| – | -$34K | -504 | Closed |
|
57
D.E. Shaw & Co
New York
| – | -$30K | -435 | Closed |
|
|
BCM
58
Brookstone Capital Management
Wheaton,
Illinois
| – | -$28K | -411 | Closed |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| – | -$10K | -146 | Closed |
|
|
CSS
60
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$6K | -89 | Closed |
|
61
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.21K | -25 | -89% |
|
62
Barclays
London,
United Kingdom
| – | +$387 | +8 | New |
|
SRRA Hedge Fund Activity: Q2 2019 in Review
49 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q2 2019, worth a combined $21.9M — down 73% from $81.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SRRA and 3 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 15 added.
The largest buyer was 683 Capital Management, adding an estimated $860K. The largest seller was Broadfin Capital, exiting entirely with an estimated $8.26M sold.
- 49 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q2 2019, down from 59 in Q1 2019.
- Funds reported $21.9M of Sierra Oncology, Inc. Common Stock stock for Q2 2019, down 73% quarter-over-quarter.
- 3 funds opened new Sierra Oncology, Inc. Common Stock positions in Q2 2019 and 13 closed out, a net change of -10 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q2 2019 was 683 Capital Management, an estimated $860K added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q2 2019 was Broadfin Capital, an estimated $8.26M sold.
Based on aggregated 13F filings for Q2 2019.